Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

About this update from Aytu Biopharma, Inc.

Company to conduct 1x1 meetings on April 24, 2025 DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time). Josh Disbrow, CEO of Aytu, will be hosting the presentation and answering questions at the conclusion. Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub Date: Wednesday, April 23, 2025 Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time) Location: Track 3 - Chablis at the Paris Hotel & Casino in Las Vegas, NV Webcast: https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/TAxDfjTKnVPjtQrR4ybMca If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company's investor relations team at [email protected] . 1x1 meetings will be scheduled and conducted in person on April 24, 2025, at the conference venue: Paris Hotel & Casino in Las Vegas, NV About Aytu BioPharma, Inc. Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com . Contacts for Investors Ryan Selhorn, Chief Financial Officer Aytu BioPharma, Inc. [email protected] Robert Blum or Roger Weiss Lytham Partners [email protected] SOURCE: Aytu BioPharma, Inc. View the original press release on ACCESS Newswire

View stock analysis, news, and events for Aytu Biopharma, Inc.